Outcomes of living donor liver transplantation for acute liver failure: The adult‐to‐adult living donor liver transplantation cohort study

Jeffrey Campsen, Andres T. Blei, Jean C. Emond, James E. Everhart, Chris E. Freise, Anna S. Lok, Sammy Saab, Karen A. Wisniewski, James F. Trotter, Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study Group – 28 August 2008 – For acute liver failure (ALF), living donor liver transplantation (LDLT) may reduce waiting time and provide better timing compared to deceased donor liver transplantation (DDLT).

Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: Insight into the interplay between hepatitis C virus infection and cellular immunity

Michel Mendler, Hansen Kwok, Edson Franco, Pedro Baron, Jill Weissman, Okechukwu Ojogho – 28 August 2008 – Peripheral blood CD4+ adenosine triphosphate [ATP (ng/mL)] release [ImmuKnow Immune Cell Function Assay (ATP)] correlates to immunoreactivity. We hypothesized that ATP levels could provide insight into hepatitis C virus (HCV) infection and recurrent liver disease in liver transplantation (LT). We studied our center's LT cohort, in which ATP levels had been measured off protocol from February 2005 through July 2006.

Long‐term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients

Marion Margaret Aw, Anita Verma, Mohamed Rela, Nigel Heaton, Giorgina Mieli‐Vergani, Anil Dhawan – 28 August 2008 – Mycophenolate mofetil (MMF) has been used to rescue liver allografts with steroid‐resistant rejection (SRR). However, the long‐term outcome of these patients is not known. This study evaluates the long‐term outcome of MMF rescue therapy for SRR in pediatric liver allograft recipients. Twenty‐six children (who received 28 liver transplants), including 16 girls, were given MMF for SRR. The median age at transplant was 1.7 (range 0.4‐13.6) years.

Subscribe to